NEWS
Artificial Life Announces
Partnership Agreement with Biotech Technology Leader BeFutur Biotechnologies
S.A.
NEW YORK, GENEVA, and MONTREAL, Oct. 15 /PRNewswire/
-- New York based Artificial Life Inc. (OTC Bulletin Board: ALIF),
a leading provider of award winning intelligent software robot (bot)
technology and specialist for computational biotech applications,
announced today that it has entered into a partnership agreement
with the Swiss/Canadian privately held biotech company BeFutur Biotechnologies
SA, a technology leader in stem cell research and regenerative medicine.
The two companies have agreed to co-operate
in the areas of
-- stem cells research
-- simulation and analysis of cell growth patterns
-- regenerative medicine
-- product and vaccine development
"This is a great jump start for us in
the biotech arena. Like us, BeFutur is a technology leader and an
innovative and dynamically growing company with an enthusiastic
founder and employees. We all are excited to co-operate with BeFutur
to simulate cell growth patterns with our unique technology to speed
up, improve and augment the manual lab research and product development
at BeFutur. The potential of the combination of our simulation and
data mining tools with the know-how and unique serum free cell technology
of BeFutur is tremendous" said Eberhard Schoeneburg, CEO of
Artificial Life.
"BeFutur Biotechnologies is honored
to be associated with Artificial Life; their data mining and Alife
simulation technology can be applied and adapted to all kinds of
complex biotech data and stem cell development patterns. Our breakthrough
results in stem cell research, combined with their algorithms derived
from the study of living systems can have a tremendous impact in
real life applications", said Carla-Maria Khanjian, Vice-President
of BeFutur Biotechnologies SA.
About Artificial Life
Founded in 1994, Artificial Life, Inc. (OTC Bulletin Board: ALIF)
develops, markets, and supports intelligent award winning and patent
pending software robots and is a leading provider of data- and knowledge
mining algorithms and biotech solutions. The company offers a variety
of unique product suites for a wide variety of Internet based applications
such as self-help, self-service, consultative selling, e-CRM, e-Finance
and Mobile Computing. Major customers of Artificial Life include,
among others, Advance Bank, Credit Suisse First Boston, Eagle Star,
Liechtenstein Global Trust, MobilCom, Pioneer Investments, PricewaterhouseCoopers,
UBS and ZDF.
Artificial Life, Inc. is headquartered in
New York City, NY, U.S.A, and maintains a subsidiary in Hong Kong.
Detailed information about Artificial Life, Inc. and its products
is available at http://www.artificial-life.com
Contact: E.Schoeneburg, CEO Artificial Life,
Inc.
E-mail: es@artificial-life.com
About BeFutur Biotechnologies
Founded in 1998, BeFutur Biotechnologies is a privately-held Swiss
biotech company with a very specialized R&D team. BeFutur is
on the forefront of research for harvesting adult autologous stem
cells. It is the only company in the world that uses a totally animal
serum free medium, thereby avoiding any risk of rejection and contamination.
Its unique technology is based on a stable cell-culture method,
which harvests cells usable in future cell therapies. Its research
activities remain in stem cell differentiation to tissue engineering,
with a primary focus on tissue regeneration. BeFutur Biotechnologies
S.A. is headquartered in Geneva, Switzerland, with subsidiaries
in Montreal, Canada and Mougins, France. More information can be
obtained at: http://www.befutur.com
Contact: Carla-Maria Khanjian, VP, BeFutur
Biotechnologies,
Email: carla@befutur.com
"Safe Harbor" Statement under the
Private Securities Litigation Reform Act of 1995: Statements in
this press release regarding Artificial Life, Inc.'s business which
are not historical facts are "forward-looking statements"
that involve risks and uncertainties. For a discussion of such risks
and uncertainties, which could cause actual results to differ from
those contained in the forward-looking statements, see the "Risk
Factors" described in the Company's Annual Report or Forms
10-K or 10-Q for the most recently ended fiscal year and quarter.
All information set forth in this press release is as of August
20, 2001, and Artificial Life, Inc. undertakes no duty to update
this information unless required by law.
BeFutur Biotechnologies is a registered trademark.
SOURCE Artificial Life, Inc.
Web Site: http://www.artificial-life.com
Breaking News on Stem Cells
Stem Cells research based on non-embryonic cells
BeFutur Biotechnologies is on the forefront of research
for harvesting non-embryonic stem cells. It is the only company
in the world that uses a totally animal serum free medium, in order
to avoid any risk of contamination. Its technology is based on the
cell-culture medium and its protocol: this particular medium plays
a screening role, which is ideal in detecting the stem cells. Harvesting
these real stem cells from adult stem cells requires an arduous
task; BeFutur Biotechnologies is on its way to achieve that milestone.
The miracle cure offered by BeFutur
Moreover, BeFutur has, through its own research,
elaborated a perfectly nutrient serum-free
medium where cells can proliferate in a healthy and normal way.
From another point of view, considering the actual controversy and
possible ban on embryonic stem cell research, BeFutur Biotechnologies
continues to watch its fantastic results poured in from its own
non-embryonic stem cells research, based on adult autologous stem
cells. "The adult autologous stem cells can function as well, perhaps
even better, than stem cells", according to the R&D team of BeFutur
Biotechnologies.
State of the art, cell-culture facility in Switzerland
BeFutur Biotechnologies and its subsidiaries are
setting up an exclusive center in Switzerland, specialized in the
culture of cells and tissues for therapeutic purposes. To date the
phase of research and development in the fields of cardiology, bio-cosmetic,
aesthetic medicine and parodontology is finished, and BeFutur is
fully operational for the industrial phase and the marketing.
Sponsor at the Techvest's annual conference on Tissue
Repair, Replacement and Regeneration
October 23-24 at Boston Marriott Long Wharf Hotel.
BeFutur Biotechnologies is a Gold Sponsor at The
Second Annual Conference on Regenerative Medicine: Rebuilding the
Human Body
December 2 - 4, Washington D.C., USA
BeFutur Biotechnologies presents breakthrough paper
at the University of Geneva workshop: "Cardiac Aging, Heart
Failure and Cell Therapy"
University of Geneva, Faculty of Medicine
September 27 - 29, Geneva, Switzerland
BeFutur Biotechnologies participates at BioContact
2001
October 10 - 12, Chateau Frontenac, Quebec
BioContact Québec 2001 is a biopharmaceutical partnership
symposium
gathering over 1200 participants
www.biocontact.qc.ca
BeFutur Biotechnologies holds a seminar on Aesthetical
Medicine in Belgium
October 31, La Woluwe, Belgium
Michel Zbili, M.D., Guest Speaker
|
